Related Experiment Video
Updated: Jun 25, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
38.9K
Psoriasis Comorbidities and Their Treatment Impact
Mark Taliercio1, Mark Lebwohl2
1Department of Dermatology Clinical Trials, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, 5th Floor, New York, NY 10029, USA.
Dermatologic Clinics
|May 25, 2024
Summary
Psoriasis is a systemic inflammatory disease affecting organs beyond the skin. This review covers its comorbidities, including screening, diagnosis, and emerging treatments for comprehensive patient care.
Area of Science:
- Dermatology
- Rheumatology
- Internal Medicine
Background:
- Psoriasis is a chronic inflammatory condition with systemic implications.
- Cutaneous manifestations are well-known, but extra-cutaneous involvement is significant.
- Understanding comorbidities is crucial for holistic patient management.
Purpose of the Study:
- To review the prevalence and clinical features of psoriasis comorbidities.
- To outline screening and diagnostic laboratory testing for these conditions.
- To discuss current and future treatment strategies for managing psoriasis-related comorbidities.
Main Methods:
- Literature review focusing on systemic inflammation in psoriasis.
- Analysis of studies on extra-cutaneous manifestations.
- Synthesis of diagnostic criteria and therapeutic approaches.
Main Results:
- Psoriasis is associated with a high burden of comorbidities across multiple organ systems.
- Effective screening and diagnostic tools are available for early detection.
- Integrated treatment plans are essential, with novel therapies on the horizon.
Conclusions:
- Psoriasis management requires a multidisciplinary approach addressing systemic involvement.
- Early identification and treatment of comorbidities improve patient outcomes.
- Ongoing research promises advanced therapeutic options for psoriasis and its related conditions.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
01:29Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
01:29Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
01:28Drug Therapy
42
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
42